	US 12,433,888 B1
	Methods and systems for treating disease using an ATR/Chk1 signaling pathway inhibitor
Peter Blume-Jensen, Cambridge, MA (US); James Dunyak, Cambridge, MA (US); Kristina Masson, Lund (SE); Ayesha Murshid, Milford, MA (US); Michail Shipitsin, Brookline, MA (US); and Caroline Maria Wigerup, Dalby (SE)
Assigned to Acrivon Therapeutics, Inc., Watertown, MA (US)
Filed by Acrivon Therapeutics, Inc., Watertown, MA (US)
Filed on Mar. 11, 2025, as Appl. No. 19/076,811.
Application 19/076,811 is a continuation of application No. 18/993,467, previously published as PCT/US2023/027579, filed on Jul. 13, 2023.
Claims priority of provisional application 63/388,914, filed on Jul. 13, 2022.
Int. Cl. A61K 31/497 (2006.01); A61K 45/06 (2006.01); G01N 33/574 (2006.01)

CPC A61K 31/497 (2013.01) [A61K 45/06 (2013.01); G01N 33/57449 (2013.01); G01N 2440/14 (2013.01)]

27 Claims

1. A method of treating a cancer comprising a step of:

administering a prexasertib or a pharmaceutically acceptable salt thereof to a subject whose cancer cell tissue sample has been determined to exhibit a Response-Predictive Signature;

wherein the Response-Predictive Signature comprises:

(a) a first biomarker score that is greater than or equal to a first predictive threshold, wherein the first biomarker is Ser296 phosphorylated Chk1;

(b) a second biomarker score that is greater than or equal to a second predictive threshold, wherein the second biomarker is Ser473 phosphorylated Kap1; and

greater than or equal to a third predictive threshold, wherein the third biomarker is total cyclin E1;

and wherein the cancer is selected from ovarian cancer, endometrial cancer, or bladder cancer.